乙酶响应纳米粒子 (ERN):一种针对药物/基因输送的有针对性的方法
Ashok Kumar Madikonda1, Amritha Ajayakumar1, Sudeena Nadendla2
1Department of Biochemistry & Molecular Biology, Central University of Kerala, Tejaswini Hills, Periye, Kasaragod 671320, Kerala, India.
Bioorganic & medicinal chemistry
|November 18, 2024
概括
对乙酶敏感的纳米粒子通过更具体地向瘤来改善癌症药物输送. 这种方法增强了瘤部位的治疗有效载荷释放,最大限度地减少了副作用,提高了治疗效率.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 纳米粒子通过增强的透性和保留效应 (EPR) 增强药物输送到瘤.
- 传统的纳米粒子缺乏特异性,导致不高效的输送和副作用.
- 对雌激酶敏感的纳米粒子在瘤部位提供向药物释放.
研究的目的:
- 审查对雌激酶敏感纳米颗粒在药物和基因传递中的作用.
- 检查酶前药物治疗.
- 讨论PSMA向的雌激酶响应纳米颗粒在前列腺癌中的应用.
主要方法:
- 在癌症治疗中对雌激酶敏感纳米颗粒的文献综述.
- 对向药物释放机制的酶活性进行分析.
- 评估前列腺特异性膜抗原 (PSMA) 作为纳米粒子输送的目标.
主要成果:
- 对雌激酶敏感的纳米粒子在瘤中显示出更好的向和有效载荷释放.
- 雌激酶前药物策略显示出局部癌症治疗的潜力.
- 针对PSMA的纳米颗粒显示出前列腺癌治疗的前景.
结论:
- 对雌激酶敏感的纳米粒子代表了针对癌症药物和基因传递的有希望的战略.
- 需要进一步的研究来优化这些系统的临床应用.
- 这些向的纳米颗粒具有改善癌症治疗结果的巨大潜力.
相关概念视频
Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


